Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and pipeline support a wide moat, but Gilead needs strong continued innovation in HIV, solid oncology launches, and smart future acquisitions to guarantee mid-single-digit growth over our 10-year forecast.
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.01 | 44.18 | 12.55 |
Price/Book Value | 16.69 | 8.35 | 4.36 |
Price/Sales | 6.52 | 5.29 | 2.34 |
Price/Cash Flow | 13.13 | 15.88 | 9.98 |
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.75 | 0.71 | 0.52 |
Current Ratio | 1.27 | 1.32 | 0.82 |
Interest Coverage | −1.28 | 4.28 | 9.51 |
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | −0.75% | 6.27% | 11.66% |
Return on Equity (Normalized) | −2.11% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 0.26% | 9.82% | 22.63% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|Xb>B#hLg | LOCK|z# | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|W!J<^KS | LOCK|r<M | $647B | |||
| AbbVie Inc
ABBV
| LOCK|$<?@w^ | LOCK|@wh | $506B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|<Yl>@&sb | LOCK|g% | $385B | |||
| Merck & Co Inc
MRK
| LOCK|&@k<V&W | LOCK|k^K | $350B | |||
| Novartis AG ADR
NVS
| LOCK|>vQP$qv? | LOCK|n&% | $294B | |||
| AstraZeneca PLC
AZN
| LOCK|z$RQ!<@& | LOCK|rt | $265B | |||
| Amgen Inc
AMGN
| LOCK|%m@MQbKK | LOCK|>yr | $242B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Plsq&# | LOCK|!> | $171B |
United States